CCCC Q1 2025 Earnings — C4 Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

CCCCC4 Therapeutics, Inc.

$243M

Q1 2025 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$7M+138.2% YoY

Gross Profit

$7M100.0% margin

Operating Income

-$29M-402.9% margin

Net Income

-$26M-363.7% margin

EPS (Diluted)

$-0.37

QoQ Revenue Growth

+39.8%

Cash Flow

Operating Cash Flow

-$33M

Free Cash Flow

-$33M

Stock-Based Comp.

$6M

Balance Sheet

Total Assets

$320M

Total Liabilities

$124M

Stockholders' Equity

$195M

Cash & Equivalents

$51M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$7M	$3M	+138.2%
Gross Profit	$7M	$3M	+138.2%
Operating Income	-$29M	-$32M	+9.5%
Net Income	-$26M	-$28M	+7.2%